Roche Restarts Phase III Trial to Pursue EMA Approval for Elevidys
Roche is launching a new Phase III placebo-controlled trial for DMD gene therapy Elevidys after the EMA rejected the treatment last year following two patient deaths. The 72-plus-week study of roughly 100 boys is designed to meet the EMA's data requirements for a regulatory re-submission. A successful outcome would